“XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis” (2015) Acta Medica Philippina, 49(2). doi:10.47895/amp.v49i2.988.